Arrow Therapeutics HCV Compound Enters Phase I
28-Nov-2006
A-831 targets the NS5a protein and is, according to the company, the first NS5a inhibitor to enter the clinic. A-831 is the first compound from Arrow's approach to the NS5a target. A further Arrow compound, also targeting the NS5a protein but of a completely different chemical structure, is expected to enter preclinical development shortly.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.